Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
0.6300
+0.0092 (1.48%)
At close: Jul 31, 2026, 4:00 PM EDT
0.6500
+0.0200 (3.17%)
After-hours: Jul 31, 2026, 7:42 PM EDT
Jasper Therapeutics Stock Forecast
JSPR's stock price has decreased by -78.72% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 5 analysts polled by S&P Global, Jasper Therapeutics stock has a consensus rating of "Buy" and an average price target of $9.17. The average 1-year stock price forecast is 1,355.56% higher than the current stock price, while the lowest is $1.50 (+138.10%) and the highest is $20 (+3,074.60%).
Price Target: $9.17 (+1,355.56%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on May 15, 2026.
Analyst Ratings
The average analyst rating for Jasper Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 3 | 3 | 4 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| William Blair | William Blair | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jun 1, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +376.19% | May 15, 2026 |
| TD Cowen | TD Cowen | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | May 15, 2026 |
| UBS | UBS | Hold Maintains $1.5 | Hold | Maintains | $1.5 | +138.10% | Apr 2, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $20 | Buy | Reiterates | $20 | +3,074.60% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.41
from -4.40
EPS Next Year
-2.56
from -2.41
EPS and Forward PE are based on non-GAAP adjusted numbers.